ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.23
−3.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 46.0K | — | — | — | — |
| Gross Profit | (46.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 85.9M | 104.9M | 93.8M | 42.3M | 32.4M |
| SG&A Expense | 18.7M | 18.9M | 20.2M | 18.8M | 12.9M |
| General & Admin Expense | 18.8M | 18.9M | 20.2M | 18.8M | 12.9M |
| Selling & Marketing Expense | (46.0K) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 104.7M | 123.8M | 114.0M | 61.1M | 45.2M |
| Cost and Expenses | 104.7M | 123.8M | 114.0M | 61.1M | 45.2M |
| Operating Income (EBIT) | (104.7M) | (123.8M) | (114.0M) | (61.1M) | (45.2M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 7.4M | 14.3M | 10.8M | 2.4M |
| Interest Expense | 4.2M | 4.2M | 4.1M | 581.0K | — |
| Net Interest Income | 60.0K | 3.2M | 10.2M | 10.2M | 2.4M |
| Other Non-Op Income/Expense | 755.0K | 2.5M | 11.7M | 8.8M | 2.4M |
| Non-Operating Income (excl Interest) | (5.0M) | (6.7M) | (15.8M) | (9.3M) | (2.4M) |
| EBT (Pre-Tax Income) | (104.0M) | (121.3M) | (102.3M) | (52.4M) | (42.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (104.0M) | (121.3M) | (102.3M) | (52.4M) | (42.9M) |
| Earnings from Cont. Ops | (104.0M) | (121.3M) | (102.3M) | (52.4M) | (42.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (104.0M) | (121.3M) | (102.3M) | (52.4M) | (42.9M) |
| Per Share | |||||
| Basic EPS | ($1.55) | ($2.00) | ($1.71) | ($1.08) | ($1.06) |
| Diluted EPS | ($1.55) | ($2.00) | ($1.71) | ($1.08) | ($1.06) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 72.3M | 60.6M | 60.0M | 48.5M | 40.6M |
| Diluted Shares Outstanding | 72.3M | 60.6M | 60.0M | 48.6M | 40.6M |
| Profitability Metrics | |||||
| EBITDA | (99.6M) | (116.9M) | (98.1M) | (51.6M) | (42.7M) |
| D&A | 148.0K | 184.0K | 178.0K | 184.0K | 169.0K |
| EBIT | (99.7M) | (117.1M) | (98.3M) | (51.8M) | (42.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026